Institutional Fund
Venrock Adviser, LLC
New York, NYCIK 16159825 filings on record
Portfolio Value
$2.68B
Q1 2026
Holdings
33
Reported positions
New Buys
8
Opened this quarter
QoQ Change
+32.3%
from $2.02B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Apogee Therapeutics Inc26.7%
- Erasca Inc9.9%
- Oruka Therapeutics Inc7.6%
- Spyre Therapeutics Inc6.9%
- Kalvista Pharmaceuticals Inc4.9%
- Dianthus Therapeutics Inc3.7%
- Other40.3%
Portfolio Holdings
33 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Apogee Therapeutics Inc | 8.49M | $714.88M | 26.7% | 0 | Held |
| 2 | Erasca Inc | 16.38M | $265.07M | 9.9% | −1.47M | Reduced |
| 3 | Oruka Therapeutics Inc | 4.15M | $203.48M | 7.6% | 0 | Held |
| 4 | Spyre Therapeutics Inc | 3.69M | $185.89M | 6.9% | 0 | Held |
| 5 | Kalvista Pharmaceuticals Inc | 6.47M | $130.33M | 4.9% | −254.5K | Reduced |
| 6 | Dianthus Therapeutics Inc | 1.18M | $99.03M | 3.7% | +180.0K | Added |
| 7 | Galecto Inc | 3.60M | $93.33M | 3.5% | +3.60M | New |
| 8 | Ocular Therapeutix Inc | 10.35M | $87.64M | 3.3% | +3.03M | Added |
| 9 | Cogent Biosciences Inc | 2.00M | $76.98M | 2.9% | 0 | Held |
| 10 | Viridian Therapeutics Inc | 3.88M | $75.95M | 2.8% | 0 | Held |
23 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio